Infasurf Generic Name & Formulations
Calfactant (as phospholipids 35mg/mL and 0.65mg proteins/mL); susp for intratracheal administration; preservative-free.
Single-use vials (6mL)—1
Prevention and treatment of respiratory distress syndrome (RDS) in premature infants.
Infasurf Dosage and Administration
See literature. Give by intratracheal administration through an endotracheal tube. 3mL/kg birth weight per dose (as 2 aliquots of 1.5mL/kg each) every 12 hours for 3 doses.
Infasurf Boxed Warnings
Interrupt dosing if reflux of product into endotracheal tube, cyanosis, bradycardia, airway obstruction, hypoventilation, or endotracheal tube dislodgement occurs; treat; resume after stabilization. Monitor respiratory status and clinical condition frequently and carefully.
Infasurf Adverse Reactions
Cyanosis, airway obstruction, bradycardia, reflux of surfactant into endotracheal tube, requirement for mechanical ventilation, reintubation, others.
Infasurf Clinical Trials
Infasurf Patient Counseling